Ribomic Inc. (TYO:4591)
Japan · Delayed Price · Currency is JPY 97.00
+6.00 (6.59%)
At close: Mar 6, 2026
Ribomic Revenue
Ribomic had revenue of 750.00K JPY in the quarter ending December 31, 2025, with 600.93% growth. This brings the company's revenue in the last twelve months to 750.00K, down -64.40% year-over-year. In the fiscal year ending March 31, 2025, Ribomic had annual revenue of 2.00M.
Revenue (ttm)
750.00K
Revenue Growth
-64.40%
P/S Ratio
7,023.94
Revenue / Employee
30.00K
Employees
25
Market Cap
5.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 2.00M | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | 65.00M | -15.00M | -18.75% |
| Mar 31, 2022 | 80.00M | -11.00M | -12.09% |
| Mar 31, 2021 | 91.00M | -30.00M | -24.79% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 12.89B |
| Linical | 9.32B |
| Kohjin Bio | 5.07B |
| Soiken Holdings | 4.58B |
| PRISM BioLab Co.,LTD | 684.61M |
| Chiome Bioscience | 593.29M |
| Carna Biosciences | 579.06M |
| D. Western Therapeutics Institute | 387.62M |